Rodman David Malcom 4

Accession 0001672659-26-000002

CIK 0001933414other

View on SEC.gov Company Profile

Filed

Jan 5, 7:00 PM ET

Accepted

Jan 6, 7:20 PM ET

Size

44.1 KB

Accession

0001672659-26-000002

Insider Transaction Report

Form 4

Period: 2026-01-02

Mineralys Therapeutics, Inc.MLYS

Rodman David Malcom

Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
2026-01-02$1.08/sh+10,053$10,857→ 81,888 total
Exercise/Conversion
Common Stock
2026-01-02$15.44/sh+3,629$56,032→ 85,517 total
Exercise/Conversion
Common Stock
2026-01-02$10.20/sh+9,347$95,339→ 94,864 total
Exercise/Conversion
Common Stock
2026-01-02$16.00/sh+20,168$322,688→ 115,032 total
Exercise/Conversion
Common Stock
2026-01-02$14.25/sh+24,193$344,750→ 139,225 total
Sale
Common Stock
2026-01-02$35.87/sh−70,037$2,511,919→ 69,188 total
Exercise/Conversion
Common Stock
2026-01-05$1.08/sh+28,038$30,281→ 97,226 total
Exercise/Conversion
Common Stock
2026-01-05$15.44/sh+10,121$156,268→ 107,347 total
Exercise/Conversion
Common Stock
2026-01-05$10.20/sh+26,069$265,904→ 133,416 total
Exercise/Conversion
Common Stock
2026-01-05$16.00/sh+53,630$858,080→ 187,046 total
Exercise/Conversion
Common Stock
2026-01-05$14.25/sh+67,473$961,490→ 254,519 total
Sale
Common Stock
2026-01-05$34.83/sh−139,245$4,849,555→ 115,274 total
Sale
Common Stock
2026-01-05$35.53/sh−53,470$1,899,554→ 61,804 total
Exercise/Conversion
Stock Option
2026-01-02−10,053→ 72,478 total
Exercise: $1.08Exp: 2032-07-11→ Common Stock (10,053 underlying)
Exercise/Conversion
Stock Option
2026-01-02−3,629→ 16,371 total
Exercise: $15.44Exp: 2033-03-17→ Common Stock (3,629 underlying)
Exercise/Conversion
Stock Option
2026-01-02−9,347→ 160,653 total
Exercise: $10.20Exp: 2035-02-13→ Common Stock (9,347 underlying)
Exercise/Conversion
Stock Option
2026-01-02−20,168→ 84,018 total
Exercise: $16.00Exp: 2033-02-09→ Common Stock (20,168 underlying)
Exercise/Conversion
Stock Option
2026-01-02−24,193→ 175,807 total
Exercise: $14.25Exp: 2034-02-13→ Common Stock (24,193 underlying)
Exercise/Conversion
Stock Option
2026-01-05−28,038→ 44,440 total
Exercise: $1.08Exp: 2032-07-11→ Common Stock (28,038 underlying)
Exercise/Conversion
Stock Option
2026-01-05−10,121→ 6,250 total
Exercise: $15.44Exp: 2033-03-17→ Common Stock (10,121 underlying)
Exercise/Conversion
Stock Option
2026-01-05−26,069→ 134,584 total
Exercise: $10.20Exp: 2035-02-13→ Common Stock (26,069 underlying)
Exercise/Conversion
Stock Option
2026-01-05−53,630→ 30,388 total
Exercise: $16.00Exp: 2033-02-09→ Common Stock (53,630 underlying)
Exercise/Conversion
Stock Option
2026-01-05−67,473→ 108,334 total
Exercise: $14.25Exp: 2034-02-13→ Common Stock (67,473 underlying)

Footnotes (7)

[F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
[F2]This balance includes 680 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.
[F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.6550 to $36.4522. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
[F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.2100 to $35.2021. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
[F5]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.2100 to $35.7700. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
[F6]The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
[F7]The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.

Documents

1 file

4
wk-form4_1767745246.xmlPrimary
FORM 4

Issuer

Mineralys Therapeutics, Inc.

CIK 0001933414

→

Entity typeother

Related Parties

filerCIK 0001672659

Filing Metadata

Form type: 4
Filed: Jan 5, 7:00 PM ET
Accepted: Jan 6, 7:20 PM ET
Size: 44.1 KB

View on SEC.gov